The ADRs reported from clinical studies, post marketing experience and laboratory findings are listed as follows, according to system organ class.
Adverse reactions are ranked by frequency, the most frequent first, using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000) including isolated reports. With each frequency grouping adverse reactions are ranked in order of decreasing seriousness.
For all the ADRs reported from post-marketing experience and laboratory findings, it is not possible to apply any ADR frequency and therefore they are mentioned with a "not known" frequency. (See Table 2.)
Click on icon to see table/diagram/image
The following events have also been observed during clinical trials in hypertensive patients, irrespective of their causal association with the study drug: Arthralgia, asthenia, back pain, diarrhea, dizziness, headache, insomnia, libido decrease, nausea, oedema, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, viral infections.
Pediatric population: Hyperkalemia has been observed in children and adolescents aged 6 to 18 years with underlying chronic kidney disease.
Heart failure and/or post myocardial infarction: The safety profile seen in controlled-clinical studies in patients with heart failure and/or post myocardial infarction varies from the overall safety profile seen in hypertensive patients. This may relate to the patients underlying disease. ADRs that occurred in heart failure and/or post-myocardial infarction patients are listed as follows: (See Table 3.)
Click on icon to see table/diagram/image
The following events have also been observed during clinical trials in patients with heart failure and/or post-myocardial infarction irrespective of their causal association with the study drug: Arthralgia, abdominal pain, back pain, insomnia, libido decrease, neutropenia, oedema, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, viral infections.
View ADR Monitoring Form